: Atai says its depression treatment failed in a mid-stage clinical trial

0
12

Shares of Atai Life Sciences NV ATAI, -30.80% tumbled about 44% in premarket trading on Friday after the company said a Phase 2a clinical trial evaluating a ketamine therapy for treatment-resistant depression did not meet the primary endpoint. Atai’s stock has declined 60.1% over the past year, while the S&P 500 SPX, +2.28% is down 19.0%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleMarket Snapshot: Why a stock market obsessed with the Fed’s inflation fight should focus on Main Street jobs in 2023
Next article: Noncompete agreements will be a thing of the past for workers — from hairstylists to executives — if federal regulators have their way

LEAVE A REPLY

Please enter your comment!
Please enter your name here